Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

In this international trial involving 371 patients with highly drug-resistant HIV-1 infection, fostemsavir reduced the HIV-1 RNA level by 0.79 log 10 copies per milliliter during the first 8 days of treatment. At week 48, more than half the patients treated with fostemsavir and an optimized backgrou...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2020-03, Vol.382 (13), p.1232-1243
Hauptverfasser: Kozal, Michael, Aberg, Judith, Pialoux, Gilles, Cahn, Pedro, Thompson, Melanie, Molina, Jean-Michel, Grinsztejn, Beatriz, Diaz, Ricardo, Castagna, Antonella, Kumar, Princy, Latiff, Gulam, DeJesus, Edwin, Gummel, Mark, Gartland, Margaret, Pierce, Amy, Ackerman, Peter, Llamoso, Cyril, Lataillade, Max
Format: Artikel
Sprache:eng
Schlagworte:
Acquired immune deficiency syndrome
Adult
Aged
AIDS
Anti-Retroviral Agents - therapeutic use
Antiretroviral agents
Antiretroviral drugs
Binding sites
CD4 antigen
CD4 Lymphocyte Count
Drug dosages
Drug resistance
Drug Resistance, Multiple, Viral
Drug Therapy, Combination
FDA approval
Female
Glycoprotein gp120
HIV
HIV Infections - drug therapy
HIV-1 - genetics
Human immunodeficiency virus
Humans
Infections
Life Sciences
Lymphocytes T
Male
Middle Aged
Multidrug resistance
Multidrug resistant organisms
Organophosphates - therapeutic use
Piperazines - therapeutic use
Prodrugs - therapeutic use
Ribonucleic acid
RNA
RNA, Viral - blood
Viral Load - drug effects
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In this international trial involving 371 patients with highly drug-resistant HIV-1 infection, fostemsavir reduced the HIV-1 RNA level by 0.79 log 10 copies per milliliter during the first 8 days of treatment. At week 48, more than half the patients treated with fostemsavir and an optimized background regimen had a virologic response.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1902493